Cantor Fitzgerald Reiterates Neutral on Oncternal Therapeutics, Maintains $1.3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated a Neutral rating on Oncternal Therapeutics (NASDAQ:ONCT), maintaining a price target of $1.3.
September 07, 2023 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst has reiterated a Neutral rating on Oncternal Therapeutics, maintaining a price target of $1.3.
The news is directly about Oncternal Therapeutics and its rating by Cantor Fitzgerald. The reiteration of a Neutral rating indicates that the analyst sees neither a strong upside nor downside in the short term, which is why the score is 0. The maintained price target also suggests that the analyst's view on the company's valuation has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100